Group One Trading’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-394,800
| Closed | -$15.5M | – | 8665 |
|
|
2023
Q2 | $15.5M | Buy |
394,800
+302,100
| +326% | +$10.7M | 0.05% | 330 |
|
|
2023
Q1 | $2.26M | Sell |
92,700
-141,000
| -60% | -$3.09M | 0.01% | 1426 |
|
|
2022
Q4 | $5M | Sell |
233,700
-213,500
| -48% | -$4.56M | 0.01% | 1145 |
|
|
2022
Q3 | $8.02M | Buy |
447,200
+204,800
| +84% | +$2.69M | 0.02% | 856 |
|
|
2022
Q2 | $2.33M | Buy |
242,400
+13,800
| +6% | +$173K | ﹤0.01% | 1909 |
|
|
2022
Q1 | $3.85M | Sell |
228,600
-83,800
| -27% | -$1.24M | ﹤0.01% | 1755 |
|
|
2021
Q4 | $5.22M | Sell |
312,400
-497,400
| -61% | -$8.15M | ﹤0.01% | 1669 |
|
|
2021
Q3 | $13.2M | Buy |
809,800
+802,300
| +10,697% | +$8.73M | 0.01% | 871 |
|
|
2021
Q2 | $47K | Sell |
7,500
-255,700
| -97% | -$1.65M | ﹤0.01% | 6648 |
|
|
2021
Q1 | $1.63M | Buy |
263,200
+26,200
| +11% | +$159K | ﹤0.01% | 2696 |
|
|
2020
Q4 | $1.64M | Sell |
237,000
-29,200
| -11% | -$187K | ﹤0.01% | 2211 |
|
|
2020
Q3 | $1.5M | Buy |
266,200
+193,700
| +267% | +$924K | ﹤0.01% | 1833 |
|
|
2020
Q2 | $370K | Sell |
72,500
-17,800
| -20% | -$74.2K | ﹤0.01% | 2872 |
|
|
2020
Q1 | $311K | Sell |
90,300
-33,100
| -27% | -$193K | ﹤0.01% | 2402 |
|
|
2019
Q4 | $1.06M | Buy |
+123,400
| New | +$441K | 0.01% | 1826 |
|
|
2019
Q1 | – | Sell |
-22,200
| Closed | -$27K | – | 5524 |
|
|
2018
Q4 | $27K | Hold |
22,200
| – | – | ﹤0.01% | 3887 |
|
|
2018
Q3 | $52K | Sell |
22,200
-18,900
| -46% | -$47.1K | ﹤0.01% | 3950 |
|
|
2018
Q2 | $112K | Buy |
41,100
+13,800
| +51% | +$38.1K | ﹤0.01% | 3491 |
|
|
2018
Q1 | $75K | Sell |
27,300
-13,000
| -32% | -$37.7K | ﹤0.01% | 3433 |
|
|
2017
Q4 | $126K | Sell |
40,300
-14,600
| -27% | -$41K | ﹤0.01% | 3221 |
|
|
2017
Q3 | $155K | Sell |
54,900
-339,700
| -86% | -$917K | ﹤0.01% | 2947 |
|
|
2017
Q2 | $1.01M | Buy |
394,600
+259,200
| +191% | +$706K | 0.01% | 1445 |
|
|
2017
Q1 | $496K | Sell |
135,400
-69,500
| -34% | -$294K | 0.01% | 1850 |
|
|
2016
Q4 | $990K | Buy |
204,900
+149,400
| +269% | +$4.43M | 0.01% | 1327 |
|
|
2016
Q3 | $2.56M | Buy |
55,500
+21,000
| +61% | +$1.18M | 0.03% | 716 |
|
|
2016
Q2 | $1.76M | Sell |
34,500
-20,800
| -38% | -$1.03M | 0.02% | 884 |
|
|
2016
Q1 | $2.34M | Buy |
55,300
+3,800
| +7% | +$194K | 0.03% | 682 |
|
|
2015
Q4 | $4.04M | Buy |
51,500
+51,300
| +25,650% | +$2.97M | 0.05% | 462 |
|
|
2015
Q3 | $8K | Sell |
200
-9,800
| -98% | -$519K | ﹤0.01% | 4380 |
|
|
2015
Q2 | $521K | Buy |
10,000
+2,900
| +41% | +$144K | 0.01% | 1751 |
|
|
2015
Q1 | $330K | Buy |
7,100
+6,000
| +545% | +$311K | 0.01% | 1954 |
|
|
2014
Q4 | $49K | Hold |
1,100
| – | – | ﹤0.01% | 3380 |
|
|
2014
Q3 | $43K | Sell |
1,100
-2,400
| -69% | -$94.2K | ﹤0.01% | 3630 |
|
|
2014
Q2 | $148K | Sell |
3,500
-700
| -17% | -$25.7K | ﹤0.01% | 2648 |
|
|
2014
Q1 | $150K | Buy |
4,200
+2,500
| +147% | +$84.3K | ﹤0.01% | 2691 |
|
|
2013
Q4 | $55K | Buy |
+1,700
| New | +$50.4K | ﹤0.01% | 3540 |
|
Group One Trading's ISEE Position: Q2 2023 in Review
Group One Trading sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q2 2023, closing a stake of 1,712 shares — an estimated $60.4K sold.
Group One Trading first reported a position in ISEE in Q4 2013 and held it in 21 quarters. The position peaked at $4.46M in Q3 2022. 256 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.
- Group One Trading reported no remaining IVERIC bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Group One Trading sold 1,712 IVERIC bio, Inc. Common Stock shares in Q2 2023, an estimated $60.4K.
- Group One Trading first reported a position in IVERIC bio, Inc. Common Stock in Q4 2013 and held it in 21 quarters.
- Group One Trading's IVERIC bio, Inc. Common Stock position peaked at $4.46M in Q3 2022.
- 256 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q2 2023.
Based on Group One Trading's 13F filing for Q2 2023, filed 9 Aug 2023.